Why Soliton Sold Off on Good News from the FDA

As highly anticipated, medical device maker Soliton (SOLY) announced the company received approval from the FDA for the cellulite indication of its Rapid Acoustic Pulse (“RAP”) technology. SOLY initially opened on February 1st with a 17.3% gain, but the stock ended the day with a 3.6% gain. Why did Soliton sell off after this good … Read more

Soliton: What Awaits the Stock After News on Cellulite Trial

“The Company’s cash, cash equivalents and restricted cash on hand is sufficient to fund the Company’s operations into December 2020 but not beyond.” This quote from the May 14 earnings report from Soliton (SOLY) is tattooed in my mind as I consider the implications of the company’s recent good news on cellulite treatment. On June … Read more